Industry Segments and Financial Information About Foreign and Domestic Operations

12 Months Ended

Sep. 30, 2018

Industry Segments and Financial Information About Foreign and Domestic Operations [Abstract]

Industry Segments and Financial Information About Foreign and Domestic Operations

Note 14 – Industry Segments and Financial Information about Foreign and Domestic Operations

The Company currently operates in two reporting segments: Commercial and Research and Development. The Commercial segment consists of FC2 and PREBOOST.  The Research and Development segment consists of multiple drug products under clinical development for oncology and urology.  There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of non-operating expenses and income taxes. Our chief operating decision-maker (“CODM”) is Mitchell S. Steiner, M.D., our Chairman, President and Chief Executive Officer.

Information about the Company's operations by segment and geographic area is as follows:

	Years Ended September 30,
	2018		2017
Operating (loss) income:	(In thousands)
Commercial	$	3,189	$	3,144
Research and Development		(10,808)		(3,244)
Corporate		(13,253)		(8,394)
	$	(20,872)	$	(8,494)
Net revenues:
United States	$	5,220	$	1,288
South Africa		2,961		951
Zimbabwe		2,159		2,227
Mozambique		*		1,430
Kenya		1,006		*
Other		4,518		7,759
	$	15,864	$	13,655
* Less than 5% of total revenues.

All of our net revenues, which are primarily derived from the sale of FC2, are attributed to our Commercial reporting segment. Depreciation and amortization related to long-lived assets that are not utilized in the production of FC2 are not reported as part of the reporting segments or reviewed by the CODM. These amounts are included in Corporate in the reconciliations above. Total assets are not presented by reporting segment as they are not reviewed by the CODM when evaluating the reporting segments’ performance.